About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc. is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients' immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient's own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Exchange: NYSEMKT
- Symbol: AST
Companies Related to Asterias Biotherapeutics:
- Previous Close: $3.90
- 50 Day Moving Average: $4.17
- 200 Day Moving Average: $4.00
- 52-Week Range: $2.30 - $5.80
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.74
- P/E Growth: 0.00
- Market Cap: $178.72M
- Outstanding Shares: 46,422,000
- Beta: 1.58
What is Asterias Biotherapeutics' stock symbol?
Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "AST."
Where is Asterias Biotherapeutics' stock going? Where will Asterias Biotherapeutics' stock price be in 2017?
4 analysts have issued 1 year target prices for Asterias Biotherapeutics' shares. Their predictions range from $5.50 to $10.00. On average, they expect Asterias Biotherapeutics' share price to reach $8.50 in the next twelve months.
When will Asterias Biotherapeutics announce their earnings?
Asterias Biotherapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 27th 2017.
Who owns Asterias Biotherapeutics stock?
Asterias Biotherapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Thrivent Financial for Lutherans (0.89%), State Street Corp (0.49%) and Oxford Asset Management (0.11%). Company insiders that own Asterias Biotherapeutics stock include Alfred D Kingsley, Andrew Arno, Edward Wirth, Katharine E Spink, Natale S Ricciardi, Richard T Lebuhn and Stephen Lahue Cartt.
Who bought Asterias Biotherapeutics stock? Who is buying Asterias Biotherapeutics stock?
Asterias Biotherapeutics' stock was bought by a variety of institutional investors in the last quarter, including State Street Corp and Oxford Asset Management. Company insiders that have bought Asterias Biotherapeutics stock in the last two years include Alfred D Kingsley, Andrew Arno, Natale S Ricciardi, Richard T Lebuhn and Stephen Lahue Cartt.
How do I buy Asterias Biotherapeutics stock?
Shares of Asterias Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Asterias Biotherapeutics stock cost?
One share of Asterias Biotherapeutics stock can currently be purchased for approximately $3.90.